New South Capital Management Inc. decreased its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 5.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 875,546 shares of the medical research company’s stock after selling 49,684 shares during the period. Thermo Fisher Scientific comprises approximately 3.1% of New South Capital Management Inc.’s investment portfolio, making the stock its 9th largest position. New South Capital Management Inc. owned approximately 0.22% of Thermo Fisher Scientific worth $134,484,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 2.7% in the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock valued at $3,989,193,000 after buying an additional 695,079 shares during the period. BlackRock Inc. raised its stake in Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after buying an additional 22,165,530 shares during the period. State Street Corp raised its stake in Thermo Fisher Scientific by 1.0% in the first quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock valued at $2,470,802,000 after buying an additional 164,367 shares during the period. Wellington Management Group LLP raised its stake in Thermo Fisher Scientific by 5.6% in the first quarter. Wellington Management Group LLP now owns 7,512,152 shares of the medical research company’s stock valued at $1,153,867,000 after buying an additional 398,622 shares during the period. Finally, Morgan Stanley raised its stake in Thermo Fisher Scientific by 7.6% in the first quarter. Morgan Stanley now owns 4,664,882 shares of the medical research company’s stock valued at $716,526,000 after buying an additional 327,826 shares during the period. Institutional investors and hedge funds own 87.60% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE:TMO) traded up 0.72% on Friday, hitting $177.22. 1,537,681 shares of the company’s stock traded hands. The stock has a market cap of $69.14 billion, a PE ratio of 30.87 and a beta of 1.06. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $182.87. The stock has a 50-day moving average of $176.80 and a 200-day moving average of $167.41.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same quarter last year, the business earned $2.03 earnings per share. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, equities analysts forecast that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.15 per share. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.45%.

TRADEMARK VIOLATION WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/26/new-south-capital-management-inc-sells-49684-shares-of-thermo-fisher-scientific-inc-tmo.html.

Several equities research analysts have recently commented on the company. Jefferies Group LLC upped their price objective on Thermo Fisher Scientific from $160.00 to $175.00 and gave the stock a “hold” rating in a research note on Friday, April 28th. Deutsche Bank AG set a $200.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Saturday, June 10th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday. They noted that the move was a valuation call. Wells Fargo & Company restated an “outperform” rating and issued a $200.00 price objective (up from $195.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 13th. Finally, Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. One equities research analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $188.56.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the transaction, the chief financial officer now directly owns 37,790 shares in the company, valued at approximately $6,660,865.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the transaction, the chief executive officer now owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The disclosure for this sale can be found here. Insiders have sold a total of 34,818 shares of company stock valued at $6,028,985 over the last 90 days. 0.49% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.